Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2018-10-04
Target enrollment:
Participant gender:
Summary
SPARC1613 is chemotherapeutic agent with a wide spectrum of anti-tumor activity. It is used
extensively in the treatment of advanced carcinomas of the breast, ovaries, lung, and other
solid tumors.This is pharmacokinetic study of SPARC1613 and Reference1613.